Skip to main content
Signal8
Launch Terminal

Can-Fite BioPharma Ltd. (CANF)

Can-Fite BioPharma Ltd., an Israeli clinical-stage biopharmaceutical company, specializes in the creation of small molecule therapeutic products. These treatments target a range of conditions including various cancers, inflammatory liver disorders, and erectile dysfunction. Its primary drug candidate, Piclidenoson, has successfully advanced through Phase III clinical trials for psoriasis and completed Phase II trials for COVID-19. Another promising asset, Namodenoson, is currently undergoing Phase III clinical evaluation for hepatocellular carcinoma (a form of liver cancer) and is in a Phase IIb study for non-alcoholic steatohepatitis (NASH). Furthermore, CF602 is in preclinical development, aimed at addressing erectile dysfunction. Beyond its drug pipeline, Can-Fite also commercializes a predictive biomarker blood test kit for A3AR. Strategic partnerships are also key to its operations; a licensing and collaboration agreement with CMS Medical covers the development, manufacturing, and commercialization of both Piclidenoson and Namodenoson. Additionally, the company collaborates with Univo Pharmaceuticals to identify and co-develop cannabis-derived formulations intended for various therapeutic applications, including cancer, inflammatory, autoimmune, and metabolic conditions. Originally incorporated in 1994 as Can-Fite Technologies Ltd., the company adopted its current name, Can-Fite BioPharma Ltd., in January 2001 and is headquartered in Petah Tikva, Israel.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Can-Fite BioPharma Ltd. logo

Can-Fite BioPharma Ltd.

NYSE:CANFHealthcare
-2.41%$1.62
AH$1.62+0.00%vs close
Mkt Cap$4.91M
Float1.31M
O/S3.03M
Vol
$ Vol
RVOL
Inst Own1.9%
SI2.6%
Earnings
Dilution
Can-Fite BioPharma Ltd. logoNYSE:CANF$1.62-2.41%
Upcoming Catalysts
  • NamodenosonREADOUT
    Cash runway at this date: < 1 mo
    Oct 26, 20267d ago8-K
Phase Distribution
22 lead-sponsored trials·2 active·14 completed
Phase 1/22
Phase 214
Phase 2/31
Phase 35

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
Phase
  • Phase 3
    Completed

    Trial of CF101 to Treat Patients With Dry Eye Disease

    CF101

    Keratoconjunctivitis Sicca

    Enrollment
    236
    Start
    Jul 2011
    Primary Completion
    Nov 2013
    Completion
    Dec 2013
    NCT01235234
  • Phase 3
    Terminated

    CF101 Therapy Compared to Methotrexate Therapy for Active Rheumatoid Arthritis

    CF101 1 mg, CF101 2 mg

    Rheumatoid Arthritis

    Enrollment
    244
    Start
    Oct 2017
    Primary Completion
    Nov 2020
    Completion
    Nov 2020
    NCT02647762
  • Phase 3
    Completed

    CF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis

    CF101 2mg, CF101 3mg

    Plaque Psoriasis

    Enrollment
    528
    Start
    Sep 2018
    Primary Completion
    Jan 2022
    Completion
    Apr 2022
    NCT03168256
  • Phase 3
    Recruiting

    Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis

    Namodenoson, Placebo

    Hepatocellular Carcinoma, Cirrhosis

    Enrollment
    471
    Start
    Mar 2023
    Primary Completion
    Feb 2026est.
    Completion
    Oct 2026est.
    NCT05201404
  • Phase 3
    Not yet recruiting

    A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and Efficacy

    piclidenoson, Placebo

    Plaque Psoriasis

    Enrollment
    705
    Start
    Jun 2025est.
    Primary Completion
    Dec 2027est.
    Completion
    Jun 2028est.
    NCT06643260
  • Phase 2/3
    Completed

    Trial of CF101 to Treat Patients With Psoriasis

    CF101, Placebo

    Plaque Psoriasis

    Enrollment
    293
    Start
    Jul 2011
    Primary Completion
    Mar 2015
    Completion
    May 2015
    NCT01265667
  • Phase 2
    Completed

    Oral CF101 and Methotrexate Treatment in Rheumatoid Arthritis Patients

    CF101

    Rheumatoid Arthritis

    Enrollment
    254
    Start
    Jun 2006
    Primary Completion
    Apr 2007
    Completion
    Apr 2007
    NCT00280917
  • Phase 2
    Completed

    Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca

    CF101, Placebo

    Keratoconjunctivitis Sicca

    Enrollment
    80
    Start
    Jan 2007
    Primary Completion
    May 2009
    Completion
    May 2009
    NCT00349466
  • Phase 2
    Completed

    Safety and Efficacy Study of CF101 to Treat Psoriasis

    CF101 1mg, CF101 2mg

    Plaque Psoriasis

    Enrollment
    76
    Start
    Jun 2007
    Primary Completion
    Sep 2009
    Completion
    Sep 2009
    NCT00428974
  • Phase 2
    Completed

    Oral CF101 Tablets and Methotrexate Treatment in Rheumatoid Arthritis Patients

    CF101, Placebo

    Rheumatoid Arthritis

    Enrollment
    253
    Start
    Feb 2008
    Primary Completion
    Mar 2009
    Completion
    Apr 2009
    NCT00556894
  • Phase 2
    Withdrawn

    A Study of the Efficacy and Safety of CF101 to Patients With Osteoarthritis of the Knee

    CF101, Placebo

    Osteoarthritis of the Knee

    Enrollment
    0
    Start
    Nov 2018est.
    Primary Completion
    Dec 2018est.
    Completion
    Jan 2019est.
    NCT00837291
  • Phase 2
    Completed

    Safety and Efficacy of Daily CF101 Administered Orally in Subjects With Elevated Intraocular Pressure

    CF101, Placebo for

    Ocular Hypertension, Glaucoma

    Enrollment
    89
    Start
    Oct 2010
    Primary Completion
    Dec 2016
    Completion
    Apr 2017
    NCT01033422
  • Phase 2
    Completed

    Oral CF101 Tablets Treatment in Patients With Rheumatoid Arthritis

    CF101, Placebo control

    Rheumatoid Arthritis

    Enrollment
    79
    Start
    Oct 2010
    Primary Completion
    Dec 2013
    Completion
    Dec 2013
    NCT01034306
  • Phase 2
    Withdrawn

    Safety &Efficacy of CF101 to Subjects With Uveitis

    CF101, Placebo

    Uveitis, Posterior, Uveitis, Intermediate

    Enrollment
    0
    Start
    Jan 2019est.
    Primary Completion
    Sep 2019est.
    Completion
    Oct 2019est.
    NCT01905124
  • Phase 2
    Completed

    Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC)

    CF102, Placebo

    Hepatocellular Carcinoma

    Enrollment
    78
    Start
    Sep 2014
    Primary Completion
    Nov 2017
    Completion
    Dec 2021
    NCT02128958
  • Phase 2
    Completed

    A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease

    CF102, Placebo

    Non-alcoholic Steatohepatitis (NASH)

    Enrollment
    60
    Start
    Nov 2017
    Primary Completion
    Mar 2020
    Completion
    Mar 2020
    NCT02927314
  • Phase 2
    Completed

    Piclidenoson for Treatment of COVID-19

    Piclidenoson, Placebo

    COVID-19, Coronavirus Infection

    Enrollment
    6
    Start
    Jan 2021
    Primary Completion
    Mar 2022
    Completion
    Apr 2022
    NCT04333472
  • Phase 2
    Unknown status

    Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)

    Namodenoson, Placebo

    NASH - Nonalcoholic Steatohepatitis

    Enrollment
    114
    Start
    Dec 2021
    Primary Completion
    Apr 2025est.
    Completion
    Oct 2025est.
    NCT04697810
  • Phase 2
    Recruiting

    Namodenoson Treatment of Advanced Pancreatic Cancer

    Namodenoson 25mg

    Pancreatic Adenocarcinoma, Pancreatic Cancer

    Enrollment
    20
    Start
    Nov 2024
    Primary Completion
    Jul 2026est.
    Completion
    Dec 2026est.
    NCT06387342
  • Phase 2
    Not yet recruiting

    An Open-label, Phase 2 Pilot Study on the Efficacy and Safety of Piclidenoson in Patients With Lowe Syndrome

    Piclidenoson

    Lowe Syndrome

    Enrollment
    5
    Start
    Jun 2026est.
    Primary Completion
    Aug 2027est.
    Completion
    Aug 2027est.
    NCT07410455
  • Phase 1/2
    Completed

    A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma

    CF102

    Hepatocellular Carcinoma

    Enrollment
    19
    Start
    Feb 2009
    Primary Completion
    Dec 2012
    Completion
    Dec 2013
    NCT00790218
  • Phase 1/2
    Completed

    A Phase 1/2 Study of CF102 in Patients With Chronic Hepatitis C Genotype 1

    CF 102, Placebo

    Chronic Hepatitis C

    Enrollment
    32
    Start
    Jul 2009
    Primary Completion
    Jun 2011
    Completion
    Jul 2011
    NCT00790673
Search ClinicalTrials.gov for “Can-Fite BioPharma”